Please complete the form below if you would like more information about ELIQUIS® (apixaban). One of our sales representatives will contact you in due course. Your contact details will only be used to help your local BMS/Pfizer representative respond to your request.
Confirm email address*
Which indication are you inquiring about?* (Select both if applicable)
What topic are you inquiring about?* (Select multiple if applicable)
The information you supply BMS through this form will be held and used by us solely for the purpose of responding to your request and will not be retained for any other purpose.
Please read our Privacy Notice here for more information.
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie